Jason Kolbert

Vernon Bernardino

Peter Levine

Ralph Martini

- Can-Fite BioPharma Ltd. reported a **net loss of $4.87 million** for the six months ended June 30, 2025, an increase from a net loss of $3.95 million in the prior year period. Revenues for the same period decreased by **36.07%** to **$0.20 million**.  **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:0]** **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:1]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:4]** 
- As of June 30, 2025, the company had **$6.45 million** in cash and cash equivalents and short-term deposits.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:1]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:4]**  Subsequent to this date, in July 2025, Can-Fite completed a public offering, raising **$5 million** in gross proceeds.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:1]** **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:2]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:3]** **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:8]** 
- The company's Namodenoson drug candidate achieved **over 50% enrollment** in its Phase 2a pancreatic cancer study and received **Orphan Drug Designation** from the U.S. FDA for this indication.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:0]**  Additionally, Piclidenoson demonstrated potential as a treatment for vascular dementia in a study by UCLA.  **[1536196_0001213900-25-081407_ea025460601ex99-3_canfite.htm:0]** 
- Can-Fite's history of net losses and operating cash outflows raise substantial doubt about its ability to continue as a going concern, though management expects existing financial resources to be sufficient for at least the next twelve months and plans to reduce non-essential expenses and defer certain R&D programs.  **[1536196_0001213900-25-081407_ea025460601ex99-2_canfite.htm:2]** **[1536196_0001213900-25-081407_ea025460601ex99-1_canfite.htm:5]**

Can-Fite BioPharma (CANF)